Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.

12 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 8 tests: 8 consistent, 0 inconsistent, 8 via agent-written checks.

3 integrity concerns flagged (0 high).

8 copyedit issues flagged: mostly consistency, clarity, typo.

Checked 65 references: 62 verified — 3 not checked.

6 data/code links checked; 6 live.

The manuscript requires substantive revision before submission, primarily to address the key resources fail (provider missing cell line authentication, antibody identifiers, and software version) and the ethics committee naming gap. Data/code deposition and study design details (blinding rationale, outlier handling) should also be addressed. The core clinical results appear sound based on the verification checks.

1. 1.
   HIGHrigor

   Report manufacturer, catalog numbers, and lot numbers for all investigational drugs (quemliclustat, gemcitabine, nab-paclitaxel, zimberelimab) in the Methods (Drug preparation section).

   Current text only gives drug names and doses; reviewers require source identification for reproducibility.
2. 2.
   HIGHrigor

   Provide authentication details (e.g., STR profiling) and mycoplasma testing results for all cell lines used (MIA PaCa-2, PANC-1, HCT-116, NCI-H650) in the Methods (Cell culture section).

   Lack of authentication is a common reproducibility issue; journals increasingly require this information.
3. 3.
   HIGHrigor

   Identify all antibodies used in ISH and mIF assays with vendor, catalog number, clone, and dilution in the Methods (Spatial analysis section).

   Without antibody identifiers, the biomarker analyses cannot be reproduced.
4. 4.
   HIGHdata code

   Deposit RNA-seq and spatial transcriptomics data in a public repository (e.g., GEO) and provide accession numbers in the Data Availability section.

   The paper's biomarker conclusions rely on these data; deposition is required for transparency and reproducibility.
5. 5.
   HIGHethics

   List the approving ethics committee(s)/IRB name(s) and protocol number(s) in the main text (Methods, Study design) rather than only in a supplementary table.

   A cross-reference to a supplement for the ethics committee name is insufficient per standard reporting guidelines.
6. 6.
   HIGHstatistics

   Name the statistical software (e.g., R version 4.x, SAS 9.4) and describe the procedure for verifying proportional hazards assumptions for Cox models in the Statistical Analysis section.

   Software version and assumption checks are standard expectations for statistical reporting.
7. 7.
   HIGHreporting

   Reference the CONSORT reporting guideline for clinical trials and provide the completed checklist as supplementary material.

   Adherence to CONSORT is expected for trial reports; its absence could delay or complicate review.
8. 8.
   HIGHreporting

   Share custom analysis code (e.g., R scripts for NR4A signature calculation, propensity score matching) in a public repository (GitHub/Zenodo) with a persistent DOI in the Data Availability section.

   Custom code is necessary to evaluate the biomarker and SCA analyses; its absence reduces reproducibility.
9. 9.
   HIGHrigor

   Add a statement in the Study Design section explaining the rationale for the open-label design and discuss its potential impact on investigator-assessed endpoints such as response rate.

   Open-label design is acceptable but the rationale and potential bias should be transparent.
10. 10.
    HIGHrigor

    Describe the handling of outliers and missing data for safety and efficacy analyses in the Statistical Analysis section.

    Outliers and missing data can influence results; the current Methods do not address this.
11. 11.
    MEDIUMcopyedit

    Standardize the abbreviation for the 100 mg quemliclustat arm throughout the manuscript (e.g., consistently use 'Quemli100' or 'quemliclustat 100 mg').

    Inconsistent use (e.g., 'Quemli100' vs 'Quemli 100') may confuse readers.
12. 12.
    MEDIUMcopyedit

    Ensure figure references are consistently formatted (e.g., 'Fig. 1' in text and 'Figure 1' in captions, not both).

    Minor formatting inconsistency but can be flagged during peer review.
13. 13.
    LOWreporting

    Explicitly state in the Statistical Analysis section that no multiplicity correction was applied to the numerous post hoc exploratory analyses (e.g., NR4A best cut, subgroup analyses), or clarify that these are purely descriptive.

    Multiplicity is a common concern; transparency about handling reduces potential criticism.
14. 14.
    LOWreporting

    Ensure the CONSORT flow diagram (Figure 1) legend defines all abbreviations (RP2D, PD, etc.) and explains the patient flow succinctly.

    Legends should be self-contained for accessibility.